ArticleFrontiers in public health2025

Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

Qiuji Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.